Three Leading Weight Management Treatments Compared Side-by-Side
Wegovy vs Saxenda vs Mounjaro: Understanding the Key Mechanism Differences
When comparing Wegovy vs Saxenda, both contain semaglutide as a GLP-1 receptor agonist, but differ significantly in dosing frequency and strength. Wegovy provides once-weekly injections with dose escalation from 0.25mg to 2.4mg maintenance, whilst Saxenda requires daily injections starting at 0.6mg and increasing to 3mg daily. Mounjaro represents a different approach entirely, utilising tirzepatide as a dual GIP and GLP-1 receptor agonist with weekly dosing from 2.5mg up to 15mg. This dual mechanism may offer different appetite control patterns compared to single GLP-1 treatments.
The Wegovy vs Saxenda comparison often centres on convenience, with many patients preferring weekly over daily injections for long-term adherence. Mounjaro's dual-action mechanism provides an alternative for those who may not achieve desired results with GLP-1-only treatments. All three are prescription-only medicines requiring clinical assessment and must be used alongside a reduced-calorie diet and increased physical activity. Understanding these fundamental differences helps inform your treatment choice during consultation with our experienced prescribers.
Comprehensive Pricing Analysis: Wegovy vs Saxenda vs Mounjaro Value Comparison
EverydayMeds provides transparent pricing across all three treatments, with Wegovy starting at £79.99 for the 0.25mg starter dose using discount code FIRST40. Our Wegovy pricing structure follows the mandatory dose escalation: £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Returning customers benefit from code DOSE25 applied at checkout. Saxenda and Mounjaro follow different pricing structures reflecting their unique dosing requirements and pen configurations.
When evaluating Wegovy vs Saxenda cost-effectiveness, consider the weekly versus daily dosing convenience factor alongside total monthly treatment costs. Our bundle options provide supply security without the need for frequent reordering—the Ultimate Stability Trio offers three months of Wegovy 2.4mg maintenance for £649.99. Mounjaro bundles accommodate its six-dose escalation schedule. All treatments qualify for our standard 3-working-day prescriber review, with express 24-hour options available for established patients requiring urgent supply continuation.
Clinical Evidence: STEP, SCALE, and SURMOUNT Trial Data
Wegovy's efficacy stems from the comprehensive STEP clinical trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM, 2021). Saxenda's evidence base includes the SCALE trials, whilst Mounjaro's weight management data comes from the SURMOUNT studies. Each trial utilised different populations, endpoints, and study designs, making direct percentage comparisons inappropriate.
When discussing Wegovy vs Saxenda clinical outcomes, both demonstrate significant weight management support when used alongside lifestyle interventions. Mounjaro's dual-action mechanism showed promising results in its dedicated weight management trials. All three treatments demonstrated their effects in combination with reduced-calorie diet and increased physical activity, not as standalone interventions. Individual responses vary considerably, emphasising the importance of personalised prescriber guidance during treatment selection.
How Wegovy Works: GLP-1 Receptor Agonist Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1 produced in your intestines after eating. This mechanism promotes feelings of fullness and satiety by slowing gastric emptying and acting on appetite centres in the brain. Unlike rapid-acting appetite suppressants, Wegovy works gradually to reduce food cravings and portion sizes naturally. The once-weekly injection provides consistent hormone levels, avoiding the peaks and troughs associated with daily medications. When comparing Wegovy vs Saxenda mechanisms, both utilise identical semaglutide action but with different pharmacokinetic profiles due to dosing frequency differences. This sustained GLP-1 activity may help patients maintain consistent appetite control throughout their weight management journey.
Streamlined Ordering Process: Assessment to Delivery
Beginning your Wegovy vs Saxenda comparison starts with our 3-minute online clinical assessment, covering medical history, current medications, and weight management goals. Our qualified prescribers review applications within 3 working days (24 hours express available), evaluating suitability for each treatment option based on your individual circumstances. Once approved, your chosen treatment ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication efficacy. The assessment includes detailed discussion of Wegovy vs Saxenda vs Mounjaro options, ensuring you receive the most appropriate treatment. Payment processing occurs only after prescriber approval, with discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied automatically at checkout to reach our advertised prices.
Storage and Practical Considerations: Wegovy vs Saxenda vs Mounjaro
Storage requirements differ significantly when comparing Wegovy vs Saxenda vs Mounjaro, with important implications for travel and lifestyle flexibility. Wegovy offers superior storage convenience, remaining stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Saxenda requires continuous refrigeration between doses due to its daily dosing schedule. All treatments arrive in temperature-controlled packaging and should be stored at 2-8°C when not in use. Wegovy's FlexTouch pen design provides consistent dose delivery with clear dose escalation markings, whilst Mounjaro utilises KwikPen technology. The mandatory dose escalation schedule ensures optimal tolerability—starting too high increases side effect risk without improving efficacy.
Wegovy vs Saxenda Treatment Duration and Long-term Considerations
Long-term treatment planning differs when evaluating Wegovy vs Saxenda, particularly regarding dose escalation timelines and maintenance phases. Wegovy requires 16 weeks to reach the 2.4mg maintenance dose through its structured escalation protocol, whilst Saxenda reaches its 3mg target dose within 5 weeks. Both treatments demonstrate weight regain potential upon discontinuation—STEP trial extensions showed patients regaining approximately two-thirds of lost weight within one year of stopping treatment.
This emphasises that weight management represents a long-term commitment rather than a short-term intervention. Mounjaro's extended dose range up to 15mg provides additional escalation options for patients requiring higher doses. When comparing Wegovy vs Saxenda for sustained treatment, weekly dosing may offer better long-term adherence compared to daily injections. Our prescribers provide ongoing monitoring and dose adjustment guidance to optimise treatment outcomes across all three options.
Make Your Choice: Wegovy vs Saxenda vs Mounjaro Available Now
Ready to begin your weight management journey with expert guidance on Wegovy vs Saxenda vs Mounjaro selection? EverydayMeds provides all three treatments through our comprehensive clinical service, with transparent pricing and no hidden fees. New customers save with code FIRST40, whilst returning customers benefit from DOSE25 discounts applied at checkout. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine, properly stored medication with full prescriber support. Complete your clinical assessment today to discuss which treatment aligns best with your lifestyle, medical history, and weight management goals. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which is right for you, alongside Saxenda for those preferring daily dosing flexibility.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
